Unknown

Dataset Information

0

Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.

ABSTRACT: During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.

SUBMITTER: Fabiani M 

PROVIDER: S-EPMC10416574 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.

Fabiani Massimo M   Mateo-Urdiales Alberto A   Sacco Chiara C   Rota Maria Cristina MC   Fotakis Emmanouil Alexandros EA   Petrone Daniele D   Del Manso Martina M   Siddu Andrea A   Stefanelli Paola P   Bella Antonino A   Riccardo Flavia F   Rezza Giovanni G   Palamara Anna Teresa AT   Brusaferro Silvio S   Pezzotti Patrizio P  

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 20230801 32

During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warrante  ...[more]

Similar Datasets

Unknown Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
| S-EPMC10575932 | biostudies-literature
Unknown Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
| S-EPMC9908083 | biostudies-literature
Unknown BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
| S-EPMC10663480 | biostudies-literature
Unknown Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults.
| S-EPMC10675676 | biostudies-literature
Unknown Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
| S-EPMC10996830 | biostudies-literature
Unknown Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination.
| S-EPMC10219672 | biostudies-literature
Unknown Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients
| S-EPMC10690076 | biostudies-literature
Unknown COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.
| S-EPMC10537670 | biostudies-literature
Unknown Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
| S-EPMC10892985 | biostudies-literature
Unknown Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.
| S-EPMC9973687 | biostudies-literature